Phase 3 · NCT07357415
TRIUMPH-9
A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial
Registry record
Trial details
- Trial
- TRIUMPH-9
- ClinicalTrials.gov ID
- NCT07357415
- Indication
- Obesity, Overweight
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 600
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide
- Comparator
- Not reported
- Eligible ages
- 18 Years – No maximum
- Locations
- 35 sites · Argentina, Canada, United States
- Study start
- 24 Jan 2026
- Primary completion
- 1 Oct 2028
- Study completion
- 1 Nov 2028
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 9 Jun 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Waist Circumference; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure; Percent Change from Baseline in High Sensitivity C-Reactive Protein; Change from Baseline in Impact of Weight on Quality of Life-Lite-Clinical Trials (IWQOL-Lite-CT) Total Score; Overall Treatment Satisfaction with Medication for Obesity (TS-MO) Scores; Pharmacokinetics (PK): Steady state Average Trough PK Concentration